DDInter38 DDInter150
Aldesleukin, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene. Genetic engineering techniques were used to modify the human IL-2 gene, and the resulting expression clone encodes a modified human interleukin-2. This recombinant form differs from native interleukin-2 in the following ways: a) Aldesleukin is not glycosylated because it is derived from E. coli; b) the molecule has no N-terminal alanine; the codon for this amino acid was deleted during the genetic engineering procedure; c) the molecule has serine substituted for cysteine at amino acid position 125.
Azathioprine is a prodrug of 6-mercaptopurine, first synthesized in 1956 by Gertrude Elion, William Lange, and George Hitchings in an attempt to produce a derivative of 6-mercaptopurine with a better therapeutic index.[A189678,A189687,A189690] Azathioprine is used to treat inflammatory conditions like rheumatoid arthritis and as an immunosuppressant in the prevention of renal transplant rejection. Azathiprine was granted FDA approval on 20 March 1968.
Aldesleukin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tioguanine
Tioguanine {u} (Compound) resembles {v} (Compound) Adenine
Adenine {u} (Compound) resembles {v} (Compound) Azathioprine
Aldesleukin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tioguanine
Tioguanine {u} (Compound) binds {v} (Gene) HPRT1
HPRT1 {u} (Gene) is bound by {v} (Compound) Azathioprine
Aldesleukin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Hydrocortisone
Hydrocortisone {u} (Compound) treats {v} (Disease) systemic lupus erythematosus
systemic lupus erythematosus {u} (Disease) is treated by {v} (Compound) Azathioprine
Aldesleukin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tioguanine
Tioguanine {u} (Compound) causes {v} (Side Effect) Vomiting
Vomiting {u} (Side Effect) is caused by {v} (Compound) Azathioprine
Aldesleukin {u} may lead to a major life threatening interaction when taken with {v} Leflunomide
Leflunomide {u} (Compound) treats {v} (Disease) systemic lupus erythematosus
systemic lupus erythematosus {u} (Disease) is treated by {v} (Compound) Azathioprine
Aldesleukin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Betamethasone
Betamethasone {u} (Compound) upregulates {v} (Gene) HSD17B11
HSD17B11 {u} (Gene) is upregulated by {v} (Compound) Azathioprine
Aldesleukin {u} may lead to a major life threatening interaction when taken with {v} Leflunomide
Leflunomide {u} (Compound) causes {v} (Side Effect) Toxic epidermal necrolysis
Toxic epidermal necrolysis {u} (Side Effect) is caused by {v} (Compound) Azathioprine
Aldesleukin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Prednisolone
Prednisolone {u} (Compound) downregulates {v} (Gene) RPS4Y1
RPS4Y1 {u} (Gene) is downregulated by {v} (Compound) Azathioprine
Aldesleukin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Betamethasone
Betamethasone {u} (Compound) upregulates {v} (Gene) MRPL12
MRPL12 {u} (Gene) is downregulated by {v} (Compound) Azathioprine
Aldesleukin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Amitriptyline
Amitriptyline {u} (Compound) palliates {v} (Disease) systemic lupus erythematosus
systemic lupus erythematosus {u} (Disease) is treated by {v} (Compound) Azathioprine
Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Tioguanine and Tioguanine (Compound) resembles Adenine (Compound) and Adenine (Compound) resembles Azathioprine (Compound)
Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Tioguanine and Tioguanine (Compound) binds HPRT1 (Gene) and HPRT1 (Gene) is bound by Azathioprine (Compound)
Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and Hydrocortisone (Compound) treats systemic lupus erythematosus (Disease) and systemic lupus erythematosus (Disease) is treated by Azathioprine (Compound)
Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Tioguanine and Tioguanine (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Azathioprine (Compound)
Aldesleukin may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide (Compound) treats systemic lupus erythematosus (Disease) and systemic lupus erythematosus (Disease) is treated by Azathioprine (Compound)
Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Betamethasone and Betamethasone (Compound) upregulates HSD17B11 (Gene) and HSD17B11 (Gene) is upregulated by Azathioprine (Compound)
Aldesleukin may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide (Compound) causes Toxic epidermal necrolysis (Side Effect) and Toxic epidermal necrolysis (Side Effect) is caused by Azathioprine (Compound)
Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Prednisolone and Prednisolone (Compound) downregulates RPS4Y1 (Gene) and RPS4Y1 (Gene) is downregulated by Azathioprine (Compound)
Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Betamethasone and Betamethasone (Compound) upregulates MRPL12 (Gene) and MRPL12 (Gene) is downregulated by Azathioprine (Compound)
Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Amitriptyline and Amitriptyline (Compound) palliates systemic lupus erythematosus (Disease) and systemic lupus erythematosus (Disease) is treated by Azathioprine (Compound)